Madrigal paid $25M upfront to Arrowhead for exclusive worldwide rights to ARO-PNPLA3, an RNAi therapeutic targeting PNPLA3.
Total deal value up to $1B including $975M in milestones.
Phase 1 data showed 46% liver fat reduction after single dose in PNPLA3 I148M homozygotes (30% of moderate-advanced fibrosis MASH patients).
Asset returned by J&J in 2023 after failing to advance from $3.7B partnership.
Part of Madrigal's MASH expansion post-Rezdiffra approval, including $4.4B Ribo siRNA deal and $50M Pfizer DGAT2 inhibitor license.